AB205534

Anti-FXYD3 antibody [EPR17160]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(11 Publications)

Rabbit Recombinant Monoclonal FXYD3 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 11 publications.

View Alternative Names

MAT8, PLML, FXYD3, FXYD domain-containing ion transport regulator 3, Chloride conductance inducer protein Mat-8, Mammary tumor 8 kDa protein, Phospholemman-like, Sodium/potassium-transporting ATPase subunit FXYD3

7 Images

Immunocytochemistry/ Immunofluorescence - Anti-FXYD3 antibody [EPR17160] (AB205534)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-FXYD3 antibody [EPR17160] (AB205534)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized HeLa (Human epithelial cells from cervix adenocarcinoma) cells labeling FXYD3 with ab205534 at 1/100 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining on HeLa cell line.

The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin mouse MAb (ab7291) at 1/1000 dilution followed by Goat Anti-Mouse IgG H&L (Alexa Fluor^® 594) (ab150120) secondary antibody at 1/1000 dilution (red).

The negative controls are as follows :
-ve control 1 : ab205534 at 1/100 dilution followed by Goat Anti-Mouse IgG H&L (Alexa Fluor^® 594) (ab150120) secondary antibody at 1/1000 dilution.
-ve control 2 : Anti-alpha Tubulin mouse MAb (ab7291) at 1/1000 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FXYD3 antibody [EPR17160] (AB205534)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FXYD3 antibody [EPR17160] (AB205534)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue labeling FXYD3 with ab205534 at 1/2000 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Membrane and cytoplasmic staining on human breast carcinoma is observed. Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-FXYD3 antibody [EPR17160] (AB205534)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized HT-29 (Human colorectal adenocarcinoma cell line) cells labeling FXYD3 with ab205534 at 1/100 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining on HT-29 cell line.

Flow Cytometry (Intracellular) - Anti-FXYD3 antibody [EPR17160] (AB205534)

Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-FXYD3 antibody [EPR17160] (AB205534)

Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed MCF7 (Human breast adenocarcinoma cell line) cells labeling FXYD3 with ab205534 at 1/60 dilution (red) compared with a rabbit monoclonal IgG isotype control (ab172730; black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/500 dilution was used as the secondary antibody.

Supplier Data

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-FXYD3 antibody [EPR17160] (ab205534) at 1/1000 dilution

All lanes:

Human stomach lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 9 kDa

Observed band size: 12 kDa

false

Exposure time: 3min

Supplier Data

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-FXYD3 antibody [EPR17160] (ab205534) at 1/5000 dilution

All lanes:

MCF7 (Human breast adenocarcinoma cell line) whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 9 kDa

Observed band size: 12 kDa

false

Exposure time: 30s

Supplier Data

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-FXYD3 antibody [EPR17160] (ab205534) at 1/1000 dilution

All lanes:

Human colon cancer lysate at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

Predicted band size: 9 kDa

Observed band size: 12 kDa

false

Exposure time: 3min

Carrier free

Anti-FXYD3 antibody [EPR17160] - BSA and Azide free
578 PE

PE Anti-FXYD3 antibody [EPR17160]
660 APC

APC Anti-FXYD3 antibody [EPR17160]
HRP

HRP Anti-FXYD3 antibody [EPR17160]
617 Alexa Fluor® 594

Alexa Fluor® 594 Anti-FXYD3 antibody [EPR17160]
519 Alexa Fluor® 488

Alexa Fluor® 488 Anti-FXYD3 antibody [EPR17160]
665 Alexa Fluor® 647

Alexa Fluor® 647 Anti-FXYD3 antibody [EPR17160]
603 Alexa Fluor® 568

Alexa Fluor® 568 Anti-FXYD3 antibody [EPR17160]
565 Alexa Fluor® 555

Alexa Fluor® 555 Anti-FXYD3 antibody [EPR17160]
775 Alexa Fluor® 750

Alexa Fluor® 750 Anti-FXYD3 antibody [EPR17160]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR17160

Isotype

IgG

Carrier free

Reacts with

Human

Applications

ICC/IF, Flow Cyt (Intra), IHC-P, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/60", "FlowCytIntra-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/2000", "IHCP-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

FXYD3 also known as Mat-8 plays a role as a regulatory subunit associated with the Na+/K+-ATPase pump modulating its ion transport activity. The protein has a molecular weight of approximately 10 kDa. FXYD3 is expressed in various tissues but it shows higher levels in epithelial tissues particularly in gastrointestinal and mammary tissues. The protein consists of a single transmembrane domain which suggests its function in modulating ion exchange across membranes.

Biological function summary

FXYD3 modulates ion transport processes important for maintaining cellular homeostasis. It forms part of the larger Na+/K+-ATPase complex interacting with other subunits to influence the pump's activity. This association affects the electrochemical gradients across the cell membrane impacting various cellular processes including volume regulation pH balance and nutrient uptake. Therefore FXYD3 is involved in key physiological roles in tissues where electrolyte balance is essential.

Pathways

FXYD3 integrates into ion transport and signaling pathways including the sodium ion transmembrane transport pathway. It interacts closely with proteins like the α and β subunits of the Na+/K+-ATPase in this context regulating their pump activity. This integration with the sodium ion transmembrane transport and signal transduction pathways exemplifies FXYD3’s role in cellular ion homeostasis and how it may influence specific physiological responses.

FXYD3 shows links to cancer particularly breast cancer. Altered expression of FXYD3 has been observed in malignant tissues suggesting a contribution to tumor development and progression. The relationship between FXYD3 and proteins like E-cadherin in this context may indicate its role in cellular adhesion and migration alterations seen in cancer. Another disorder linked to FXYD3 is cystic fibrosis where its modulation of ion channels could affect disease severity or progression especially regarding electrolyte transport abnormalities.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Associates with and regulates the activity of the sodium/potassium-transporting ATPase (NKA) which transports Na(+) out of the cell and K(+) into the cell (PubMed : 17077088). Reduces glutathionylation of the NKA beta-1 subunit ATP1B1, thus reversing glutathionylation-mediated inhibition of ATP1B1 (PubMed : 21454534). Induces a hyperpolarization-activated chloride current when expressed in Xenopus oocytes (PubMed : 7836447).. Isoform 1. Decreases the apparent K+ and Na+ affinity of the sodium/potassium-transporting ATPase over a large range of membrane potentials.. Isoform 2. Decreases the apparent K+ affinity of the sodium/potassium-transporting ATPase only at slightly negative and positive membrane potentials and increases the apparent Na+ affinity over a large range of membrane potentials.

See full target information FXYD3

style

left-column

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Cancer medicine 14:e70500 PubMed39783776

2025

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival.

Applications

Unspecified application

Species

Unspecified reactive species

Nathalie B Rasko,Christopher B Nahm,John Turchini,Rachel Teh,Helge Rasmussen,Sooin Byeon,Sumit Sahni,Jaswinder S Samra,Anthony J Gill,Anubhav Mittal

American journal of cancer research 14:4353-4366 PubMed39417182

2024

Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Ke Xin Yee,Yu-Cheng Lee,Hieu Duc Nguyen,Ming-Yao Chen,Yi-Chun Ni,Yung-Fu Wu,Kuen-Haur Lee

Journal of gastrointestinal oncology 15:1265-1281 PubMed38989421

2024

Identifying drug candidates for pancreatic ductal adenocarcinoma based on integrative multiomics analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Penglei Ge,Zhengfeng Wang,Weiwei Wang,Zhiqiang Gao,Dingyang Li,Huahu Guo,Shishi Qiao,Xiaowei Dang,Huayu Yang,Yang Wu

Cellular & molecular immunology 20:292-304 PubMed36693922

2023

FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjuan Yang,Rukun He,Hao Qu,Wenwen Lian,Yue Xue,Tao Wang,Wenlong Lin,Peishuo Zhu,Meng Xia,Lihua Lai,Qingqing Wang

Frontiers in oncology 12:859216 PubMed35371992

2022

Displacement of Native FXYD Protein From Na/K-ATPase With Novel FXYD Peptide Derivatives: Effects on Doxorubicin Cytotoxicity.

Applications

Unspecified application

Species

Unspecified reactive species

Chia-Chi Liu,Yeon Jae Kim,Rachel Teh,Alvaro Garcia,Elisha J Hamilton,Flemming Cornelius,Robert C Baxter,Helge H Rasmussen

Journal of cellular and molecular medicine 25:4040-4052 PubMed33621431

2021

KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.

Applications

Unspecified application

Species

Unspecified reactive species

Yu-Shui Ma,Ting-Miao Wu,Bin Qian,Yu-Shan Liu,Hua Ding,Ming-Ming Fan,Ji-Bin Liu,Fei Yu,Hui-Min Wang,Yi Shi,Li-Peng Gu,Liu Li,Lin-Lin Tian,Pei-Yao Wang,Gao-Ren Wang,Zhi-Jun Wu,Qi-Fei Zou,Chang-Chun Ling,Da Fu

Journal of cellular and molecular medicine 25:1911-1926 PubMed33350586

2020

Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Jiefeng Liu,Yuhua Feng,Xinyu Zeng,Miao He,Yujing Gong,Yiping Liu

Bioscience reports 40: PubMed32432654

2020

LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Xing Peng,Jinyu Gao,Chunyan Cai,Yumei Zhang

ACS sensors 5:928-935 PubMed32162907

2020

Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis.

Applications

Unspecified application

Species

Unspecified reactive species

Ying-Pei Hsu,Hung-Wei Yang,Nan-Si Li,Ying-Tzu Chen,Hao-Han Pang,See-Tong Pang

Molecular cancer research : MCR 17:238-249 PubMed30206184

2018

SOX9/FXYD3/Src Axis Is Critical for ER Breast Cancer Stem Cell Function.

Applications

Unspecified application

Species

Unspecified reactive species

Yue Xue,Lihua Lai,Wenwen Lian,Xintao Tu,Jiaojiao Zhou,Ping Dong,Dan Su,Xiaojia Wang,Xuetao Cao,Yiding Chen,Qingqing Wang

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-FXYD3 antibody [EPR17160]

Immunocytochemistry/ Immunofluorescence - Anti-FXYD3 antibody [EPR17160] (AB205534)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FXYD3 antibody [EPR17160] (AB205534)

Immunocytochemistry/ Immunofluorescence - Anti-FXYD3 antibody [EPR17160] (AB205534)

Flow Cytometry (Intracellular) - Anti-FXYD3 antibody [EPR17160] (AB205534)

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Western blot - Anti-FXYD3 antibody [EPR17160] (AB205534)

Related conjugates and formulations (10)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (11)

Product promise